ECM
NVCR icon

Evergreen Capital Management’s NovoCure NVCR Stock Holding History

Evergreen Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,423
Closed -$146K – 1631
2026
Q1 		$146K Buy
+13,423
New +$168K ﹤0.01% 1434

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Evergreen Capital Management's NVCR Position: Q2 2026 in Review

Evergreen Capital Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 13,423 shares — an estimated $146K sold.

Evergreen Capital Management first reported a position in NVCR in Q1 2026 and held it in 1 quarter. The position peaked at $146K in Q1 2026. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Evergreen Capital Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • Evergreen Capital Management sold 13,423 NovoCure shares in Q2 2026, an estimated $146K.
  • Evergreen Capital Management first reported a position in NovoCure in Q1 2026 and held it in 1 quarter.
  • Evergreen Capital Management's NovoCure position peaked at $146K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.